NIDA Payline 2026: No Cutoff, 11.5% New R01 Odds

For a side-by-side view of every institute, see the NIH and NSF funding odds tracker.

NIDA Payline 2026: Budget Rules Instead of a Percentile

NIDA's FY2026 policy page sets a 10% ceiling on renewal growth but no percentile. Grantsights checked the NIDA FY2026 funding policy (opens in a new tab) for any score threshold and found that the page is almost entirely about money: how much NIDA will pay per award, how fast renewals may grow, and what continuations get during a continuing resolution.

On selection, the page says one thing. Under the NIH Unified Funding Strategy, NIDA "will exercise discretion" and consider portfolio balance, programmatic importance, public health impact and other factors. Awards stay subject to programmatic adjustments from the levels NIDA's Advisory Council approved.

The wider shift is NIH's. A November 21, 2025 revision of the NIH funding decisions page (opens in a new tab) says ICs "will no longer employ these cutoff points in overall impact scores to determine which applications to fund." NIDA's page also notes that NIH runs on a continuing resolution (NOT-OD-26-131), now for FY2027. So no NIDA payline exists to look up, and any percentile you see quoted for NIDA isn't from NIDA.

NIDA's Four Cost Rules, Explained

NIDA's policy contains 4 rules that shape the size of your award. None of them sets a cutoff, but each changes how you should budget.

The "FY2025 average cost" rule doesn't name a dollar figure. According to NIH Data Book table 206, NIDA's combined R01 and R37 funding was $103.6 million across 139 awards in FY2025, an average of $744,972 per award. That's one way to read the average, but the policy doesn't say which measure NIDA uses, so treat it as context rather than a target.

The renewal rule is easier to apply. If your prior-year award was $400,000, a renewal asking for more than $440,000 needs strong justification. Applicants underestimate this when they add new aims to a renewal: the science may grow faster than the budget can. If a renewal needs much more, say why in the budget justification, tied to specific new work. The modular budget guide covers how to build that justification.

The CR rule hits current grantees. A continuation committed at $400,000 would arrive at $360,000 under the 90% rule while the CR lasts, and NIDA says future-year commitments stay unchanged.

NIDA R01 Success Rates, FY2021 to FY2025

NIDA's new R01 success rate peaked at 19.7% in FY2023 and fell to 11.5% by FY2025. These are NIH's official success-rate figures (opens in a new tab):

Source: NIH Data Book table 206 (R01, R21 and R03 rows) and table 217 (all research project grants, or RPGs).

Two years of decline, not one. NIDA's new R01 rate dropped 3.9 points in FY2024 and another 4.3 points in FY2025, as applications climbed from 922 in FY2023 to 1,089 in FY2025. Renewals fell harder in FY2025: 10 of 56 funded, against 19 of 60 the year before.

Dollars tell a longer story. According to NIH Data Book table 206, NIDA's combined R01 and R37 funding was $183.6 million in FY2022 and $165.4 million in FY2023, then $109.4 million in FY2024 and $103.6 million in FY2025. The FY2022 average award ($862,049) was the highest of the five years, and the FY2026 cost rule now holds new awards near the FY2025 average.

Two fallback routes barely exist at NIDA. The institute made 0 R56 bridge awards in FY2025 and 1 in FY2024, per table 206, and it funded no RF1 awards in FY2025. A near-miss R01 at NIDA generally means a resubmission, not a bridge. The R21 offered no better odds either: 10.4% in FY2025 (49 of 471), below the new R01 rate.

Because NIH's success rate definition (opens in a new tab) treats an A0 and an A1 within one fiscal year as one application, these are application odds rather than per-PI odds.

From Score to Award at NIDA

NIDA reviewed 1,089 new R01 applications in FY2025 and funded 125, per NIH Data Book table 206. Between your score and that decision sit three steps the policy page mentions only in passing.

First, peer review sets a recommended budget. The policy calls the reviewers the Integrated Review Group, and NIDA says it may reduce competing awards below the level they recommended "in order to increase the number of awards issued." A strong score therefore doesn't lock in the budget reviewers approved.

Second, NIDA's Advisory Council approves a level, and awards remain "subject to programmatic adjustments" from it. Council approval is a step in the process, not a funding notice. If your eRA Commons status shows Council review complete and nothing else, the decision is still open.

Third, NIDA program staff apply discretion across portfolio balance, programmatic importance and public health impact. That's where an application's fit with current NIDA priorities carries the most weight, and where a percentile alone can't predict the outcome. Two applications at the same percentile can end up on opposite sides of the line if one fills a gap in the portfolio and the other duplicates funded work.

The practical step is a short, specific question to your program officer after the summary statement arrives: does NIDA still have the application in play for this year's money, and if not, what would make the resubmission a better fit? The NIH score explainer covers what the percentile itself measures.

HIV/AIDS Applications Get Added Weight

NIDA's FY2026 policy names 1 research area for extra consideration: HIV/AIDS. Related applications "will receive additional consideration" to align with NIH's HIV/AIDS research priorities in NOT-OD-20-018 (opens in a new tab), along with their relevance to NIDA's mission.

Two conditions apply. The HIV/AIDS link has to meet NIH's priority criteria in that notice, and the project still has to fit NIDA's mission in substance use. A common mistake is adding an HIV outcome to an addiction study as an afterthought. That fails because reviewers and program staff can see when a link is cosmetic, and NIDA's policy ties the consideration to programmatic relevance, not to the label. If HIV is central to the question, say so in the aims and the abstract. If it isn't, don't force it.

The policy doesn't quantify the extra consideration, and the Data Book doesn't split NIDA's success rates by HIV/AIDS status, so there's no public number for how much the designation helps.

What FY2026 Award Records Show

In RePORTER, Grantsights found 188 new NIDA R01 and R37 awards for FY2026, the highest of the three years pulled (159 in FY2024, 130 in FY2025). These are award records, not success rates: RePORTER doesn't include unfunded applications.

Grantsights analysis of these records shows the median first-year direct cost fell by $35,108 from FY2025 to FY2026, while the number of awards rose by 58. That's consistent with a cost rule designed to spread money across more grants, though RePORTER can't show requested budgets, so it doesn't prove the cut on any single award. Multi-year funding was rare at NIDA: 5 of 188 new awards in FY2026.

Timing spread across the summer. In FY2026, August led with 43 new awards, then May (30), July (25), September (23) and June (22). In FY2025, August (36) and July (31) led.

One university in Kentucky, the University of Kentucky, had 6 new NIDA awards in FY2026, behind the University of Michigan and Johns Hopkins (8 each) and UC San Diego (7). By state, California (20), Massachusetts (18) and New York (14) led. In FY2024, Yale led with 10. To see which NIDA programs fund work like yours, search abstracts on NIH RePORTER (opens in a new tab); the R01 winners and award history guide covers R01 winners NIH-wide.

NIDA Fellowships and K Awards: The Strongest Odds

NIDA's F31 success rate rose to 41.8% in FY2025, more than three times its new R01 rate. NIDA's training mechanisms held up far better than its research grants. Rates below come from NIH Data Book tables 203 and 204:

These rates are unusually strong. For comparison, NIMH's FY2025 F31 rate was 17.7% and its K23 rate 20.0% (see the NIMH payline page). For a trainee whose project fits both institutes, NIDA's numbers are worth a close look. Assignment depends on fit, so the science has to belong at NIDA, but where it does, the F31, K01 and K23 are NIDA's best bets.

The K99 is the one weak spot, at 20.4% in FY2025. The F32 and K08 rows rest on small counts. The F31 success rate by institute and K award success rates guides show how unusual NIDA's numbers are; read the F31 and F32 fellowship guide before you apply.

What NIDA's Policy Page Doesn't Tell You

NIDA's policy gives 4 cost rules and 1 priority area, and it says almost nothing about how applications are ranked. What the public record covers, and where it stops:

The biggest omission is career stage. NIDA's FY2026 page says nothing about early stage investigators, unlike the NINDS, NIMH and NICHD pages (see the NICHD payline page for one example). That doesn't mean NIDA ignores ESI status, since NIH-wide policy still applies, but it means no NIDA-specific ESI rule is published. It's a red flag to plan as if one exists. Confirm your status in eRA Commons and read the new investigator guide.

The policy also doesn't define "strong justification" for renewal growth, and it doesn't say how far below the review group's level a new award can be cut. Ask your program officer both questions before you finalize a budget.

Next Action Table for NIDA Applicants

NIDA's 11.5% new R01 rate in FY2025 means about 9 in 10 applications missed. Use this table to pick a move:

For the revision itself, the summary statement guide shows how to sort reviewer critiques, and the resubmission guide covers the introduction page. The NIH score explainer explains what a percentile can and can't tell you. Institutes that still publish numbers include NCI (NCI payline) and NHLBI (NHLBI payline). For a sibling institute with a stated $500,000 rule, see the NINDS payline page. To find addiction and recovery research funding from foundations and state agencies, use Grantsights grant search.

Sources

• NIDA FY2026 funding policies and considerations (opens in a new tab)
• NOT-OD-20-018, NIH HIV/AIDS research priorities (opens in a new tab)
• NIH funding decisions and the Unified Funding Strategy (opens in a new tab)
• NIH Data Book success-rate tables (opens in a new tab) (tables 203, 204, 206 and 217)
• NIH success rate definition (opens in a new tab)
• NIH, Fiscal Year 2025 By the Numbers (opens in a new tab)
• NOT-OD-26-059, fiscal policies for FY2026 (opens in a new tab)
• NIH RePORTER (opens in a new tab)

Related Guides

• NIH paylines explained
• NIH R01 grant success rate data
• NIH K99/R00 winners and award history
• NIH R21 grant guide
• NIH F32 winners and award history